Nevertheless, large-scale studies are required to determine whether systematic serum measurement and/or immunohistochemical detection of β-hCG and AFP could provide prognostic or therapeutic value for patients with CRC, particularly in early-onset cases. This evidence concerns the gene AFP and colorectal carcinoma.